Genus's earnings have been declining at an average annual rate of -19.2%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 4% per year. Genus's return on equity is 9.5%, and it has net margins of 7.1%.
Key information
-19.15%
Earnings growth rate
-19.46%
EPS growth rate
Biotechs Industry Growth
17.04%
Revenue growth rate
4.05%
Return on equity
9.47%
Net Margin
7.07%
Next Earnings Update
10 Sep 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Genus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
OTCPK:GENS.F Revenue, expenses and earnings (GBP Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
672
48
129
72
30 Sep 25
672
33
128
72
30 Jun 25
673
19
127
72
31 Mar 25
672
8
121
75
31 Dec 24
672
-4
115
79
30 Sep 24
670
2
116
79
30 Jun 24
669
8
116
79
31 Mar 24
671
21
114
78
31 Dec 23
673
33
111
77
30 Sep 23
681
33
111
77
30 Jun 23
690
33
110
77
31 Mar 23
676
34
100
75
31 Dec 22
662
34
90
73
30 Sep 22
628
38
89
73
30 Jun 22
593
41
89
73
31 Mar 22
582
39
92
71
31 Dec 21
570
37
95
68
30 Sep 21
572
42
96
68
30 Jun 21
574
47
97
68
31 Mar 21
570
45
93
70
31 Dec 20
566
42
89
71
30 Sep 20
559
39
89
71
30 Jun 20
551
35
88
71
31 Mar 20
536
37
80
66
31 Dec 19
520
39
72
61
30 Sep 19
504
23
72
61
30 Jun 19
489
8
72
61
31 Mar 19
480
1
76
56
31 Dec 18
471
-7
81
51
30 Sep 18
470
18
81
51
30 Jun 18
470
43
82
51
31 Mar 18
473
55
80
48
31 Dec 17
476
67
79
45
30 Sep 17
467
50
79
45
30 Jun 17
459
33
78
45
31 Mar 17
441
40
75
40
31 Dec 16
422
47
71
34
30 Sep 16
405
48
71
34
30 Jun 16
388
49
71
34
31 Mar 16
388
40
68
32
31 Dec 15
388
31
64
29
30 Sep 15
393
35
64
29
Quality Earnings: GENS.F has a large one-off loss of £17.3M impacting its last 12 months of financial results to 31st December, 2025.
Growing Profit Margin: GENS.F became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GENS.F's earnings have declined by 19.2% per year over the past 5 years.
Accelerating Growth: GENS.F has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GENS.F has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).
Return on Equity
High ROE: GENS.F's Return on Equity (9.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/04 01:53
End of Day Share Price
2026/05/13 00:00
Earnings
2025/12/31
Annual Earnings
2025/06/30
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genus plc is covered by 18 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.